Fulcrum Therapeutics, Inc.FULCNASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$-75M

-670.0% YoY

Free Cash Flow

$-60M

Revenue CAGR (5Y)

—

Marginsimproving

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	19	6↓66.9%	3↓55.8%	80↑2752.0%	0
Gross Profit	-51	-70↓39.4%	3↑104.0%	17↑492.3%	-1↓108.4%
Operating Income	-81	-113↓38.9%	-111↑1.7%	-22↑80.2%	-85↓287.1%
Net Income	-81	-110↓35.9%	-97↑11.4%	-10↑90.0%	-75↓670.0%
EBITDA	-79	-110↓39.7%	-108↑1.1%	-18↑83.2%	-73↓302.9%
EPS Diluted	-2.22	-2.35↓5.9%	-1.59↑32.3%	-0.16↑89.9%	-1.18↓637.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	35	35↓0.9%	26↓27.2%	58↑127.7%	198↑239.3%
Total Current Assets	226	208↓8.2%	242↑16.7%	250↑3.2%	357↑43.0%
Total Assets	235	227↓3.5%	258↑13.7%	261↑1.2%	366↑40.5%
Total Current Liabilities	19	17↓12.9%	14↓18.2%	11↓19.2%	13↑18.1%
Total Liabilities	23	28↑18.3%	23↓18.9%	18↓21.4%	17↓2.3%
Total Equity	212	199↓6.0%	235↑18.2%	243↑3.3%	349↑43.6%
Total Debt	0	13	11↓19.4%	9↓20.3%	6↓25.3%
Net Debt	-35	-22↑38.8%	-15↑32.0%	-50↓236.3%	-191↓285.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-78	-97↓23.7%	-91↑6.3%	-2↑97.6%	-60↓2608.1%
Capital Expenditure	-2	-2↓14.6%	-1↑74.1%	-0↑45.3%	-0↓12.9%
Free Cash Flow	-80	-99↓23.5%	-91↑7.6%	-2↑97.3%	-60↓2319.0%
Stock-Based Comp	11	13↑20.6%	15↑10.9%	15↓1.7%	12↓14.3%
Net Change in Cash	-22	-0↑98.5%	-10↓2936.6%	33↑443.6%	139↑325.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance